FOLD - Company ID 0001178879
The table below shows AMICUS THERAPEUTICS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $7.76M | -$29.70M | -$18.07M | -$58.31M | -$72.35M | -$107.94M |
| Capital expenditure | $212.00K | $1.81M | $1.94M | $871.00K | $868.00K | $806.00K |
| Investing cash flow | -$32.86M | $7.54M | $36.26M | $58.21M | $86.56M | $93.25M |
| Dividends paid | - | - | - | - |
AMICUS THERAPEUTICS, INC. reported operating cash flow of $33.15M for fiscal year 2025. That is up 197.8% from -$33.89M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$150.15M (FY 2016) to $33.15M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$11.70M | -$13.31M | -$7.83M | -$8.15M | $8.83M | -$1.49M |